Remember meForgot password?
    Log in with Twitter
Press Release

Phenylketonuria (PKU) - Market Insights, Epidemiology and Market Forecast-2027

DelveInsight Business Research LLP

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 01/23/2019 -- Phenylketonuria (PKU) - Market Insights, Epidemiology and Market Forecast-2027

21 January 2019

Currently, there are around 16,500 people living with PKU in the United States.

1. Phenylketonuria (known as PKU) is an inherited disorder that increases the levels of a substance called Phenylalanine in the blood.
2. The overall prevalence of HPA (hyperphenylalaninemia)/PKU phenotypes in the European population approximates at around 1/10,000 births.
3. PKU is classified, based on its severity level, into Classic PKU (55%), Mild PKU (28%) and Mild HPA (hyperphenylalaninemia) (18%).

(Albany, US) DelveInsight launched a new report on Phenylketonuria (PKU) - Market Insights, Epidemiology and Market Forecast-2027

Key topics covered

1) The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms and diagnostic trends.
2) It provides the insights about historical and current patient pool and forecasted trend for 7 major markets, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.
3) The report encloses the detailed analysis of marketed drugs, Phase III and late Phase II pipeline drugs.
4) The market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
5) The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Phenylketonuria (PKU) market.

"Despite the recent advances in the management of phenylketonuria, there is an unmet need regarding the management of this disorder."

The prevailing treatment is predominantly through dietary restriction of Phenylalanine (Phe) to the minimum required for normal growth, supplemented with specifically designed medical foods. Therefore, the first line of therapy for PKU treatment is Dietary therapy, where low Phe diet is supplemented with amino acid formulas, which commences soon after diagnosis. Although dietary treatment has been successful in preventing intellectual disability in the early treated PKU patients, there are major issues with dietary compliance due to palatability of the diet.

Advances in dietary therapy, such as the use of large neutral amino acids (LNAA) and glycomacropeptides (GMP), have been explored. Other essential amino acids are supplemented using various medical foods, vitamins, minerals, and other micronutrients; and are followed closely. Special PKU diet includes the recommendation of a low-phenylalanine formula with specialized protein. Gene therapy and enzyme replacement or substitution therapy have also proved to be more promising in the recent years, however, long term studies are still needed to understand the full impact of these treatments.

The dynamics of Phenylketonuria market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2018-2027.

To summarize, the expected launch of potential drug candidates along with positively changing healthcare dynamics is believed to accentuate the market revenue of Phenylketonuria in the 7MM during the study period (2016-2027). The report will benefit by providing companies and their drugs that are involved in Phenylketonuria market.

Companies covered

1. Synlogic
2. Censa Pharmaceuticals
3. Codexis
And many others

Drugs covered

1. SYNB-1618
2. CNSA-001
And many others

Table of contents

1. Report Introduction
2. Phenylketonuria (PKU): Market Overview at a Glance
3. Disease Background and Overview: Phenylketonuria (PKU)
4. Epidemiology and Patient Population
4.1. 7MM Total Prevalent Cases of Phenylketonuria (PKU) (2016-2027)
4.2. 7MM Severity based Cases of Phenylketonuria (PKU) (2016-2027)
4.3. 7MM Diagnosed and Treatable Cases of Phenylketonuria (PKU) (2016-2027)
5. Phenylketonuria (PKU) : Country- Wise Epidemiology
5.1. United States
5.1.1. Prevalent Cases of Phenylketonuria (PKU) (2016-2027)
5.2. EU-5
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
6. Treatments & Medical Practices
7. Marketed Product
7.1. Palynziq: BioMarin Pharmaceutical
7.2. Kuvan: BioMarin Pharmaceutical
8. Emerging Therapies
8.1. Key Cross Competition
8.2. SYNB-1618: Synlogic
8.3. CNSA-001: Censa Pharmaceuticals
9. Phenylketonuria (PKU) : Market Size
10. 7MM: Country-Wise Market Analysis
11. Market Drivers
12. Market Barriers
13. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
SOURCE DelveInsight

For more information on this press release visit:

Media Relations Contact

Ankit Nigam
Digital Marketing Specialist
Delveinsight Business Research LLP
Telephone: 9650213330
Email: Click to Email Ankit Nigam

Latest News
Top News